Falk Forum
Dedicated to IBD
To commemorate IBD month, Dr Falk Pharma Australia, in partnership with Crohn’s Colitis Cure, held a one-day Dedicated to IBD meeting in Sydney on 27 May 2023. This over-subscribed event featured leading experts in the field from across Australia, who discussed and debated the latest strategies in IBD management and overall patient care.

Whether you were unable to attend the meeting, or if you attended and would like to revisit, you can do so here at a time that suits you.

The opinions expressed by the speakers during this meeting are not necessarily those of Dr Falk Pharma Australia. Some of the therapeutic interventions discussed during this meeting are not currently TGA-approved.

WATCH THE SESSIONS

Play Video

Introduction

Prof Jane Andrews
Royal Adelaide Hospital, SA
Play Video

Benchmarking and Quality Care in IBD

Dr Gareth Walker
Royal Brisbane and Women’s Hospital

Panel discussion

Dr Gareth Walker, Dr Simon Ghaly, Dr Yoon-Kyo An, Dr Alice Bennett, Prof Jane Andrews
How do you persuade people to get involved with measuring for improvement rather than measuring for penalty?
How do we close the gap and increase our quality of care for rural patients, especially as they may be lacking in multidisciplinary team services?
Why do you think medicine, particularly IBD, has been slow to apply proven behavioural science knowledge compared with other industries?
Audience comment: We need to move away from ‘expert consensus’ and move towards representation.
What are the discussions around activity-based funding at the management level?
Audience comment: Patient experience, preferences and values are important to quality improvement initiatives.
Have we any examples how measuring performance helped with funding or government action?
Audience comment: Rural services need more funding to improve service delivery.
Audience comment: The message about benchmarking activities should be simple to get buy-in from all stakeholders.
Audience comment: Discussion: Artificial intelligence can be used to improve patient-centred care but technology use can also increase inequality of care.
Play Video

Debate: 5ASAs are Being Underutilised in Ulcerative Colitis

Dr Yoon-Kyo An
Mater Hospital, QLD
Professor Peter Gibson
Monash University, VIC
Watch this engaging debate with Dr Yoon-Kyo An taking the affirmative position.

Debate outcomes

Adjudicator summary
Audience vote
Play Video

Crohn’s Colitis Cure

Prof Jane Andrews
Royal Adelaide Hospital
Mr Bill Petch
Mr Bill Petch
Discover more about the charity Crohn’s Colitis Cure and the potential benefits of the CCCare platform.
Play Video

New Oral Therapies in Prime Time; Which, When, Why and How?

  1. Tofacitinib vs Upadacitinib
  2. Ozanimod, why the concern?

Prof Rupert Leong
Concord Hospital, NSW
This session focuses on specific small molecule drugs and how to use them optimally in IBD.
Introductory remarks by Prof Susan Connor

Panel discussion

Prof Rupert Leong, A/Prof Jonathan Segal, Prof Susan Connor, Dr Claire Gordon
Can you explain the use of tofacitinib after infliximab with acute severe colitis?
Should there be advocacy for financial access to the non-live zoster vaccine for people with IBD?
Do we have data on drug withdrawal? Is there a rebound phenomenon?
In people who have bio-failed and dose de-escalated from, say 10 mg bd tofacitinib, would you ever drop the dose?
Play Video

Maximising Gains, Minimising Risks of Biologics and Beyond

A/Prof Jakob Begun
Mater Hospital, QLD
Understand A/Professor Begun’s approach to biologic treatments in IBD and the importance of defining treatment goals and stratifying disease early.

Panel discussion

A/Prof Jakob Begun, Prof Rupert Leong, A/Prof Jonathan Segal, Prof Susan Connor, Dr Claire Gordon
Should people who are older, frail or with comorbidities be treated to the same targets as the general IBD population?
Can you get shingles if you have been vaccinated but never had an actual primary varicella zoster infection?
At what point after a patient has started on thiopurine are they assessed for treatment benefit?
In a patient with skin cancers, at what point do you stop the thiopurine?
We now have a number of small molecule and biologic treatments for ulcerative colitis. At what point is it enough?
Play Video

Case study

Dr Claire Gordon
Sir Charles Gairdner Hospital, WA
This case discussion focuses on thiopurines and the considerations around their long-term use in IBD.

This case study was kindly provided by Prof Ian Lawrance.
Play Video

Travel and IBD

Dr Astrid-Jane Williams
Liverpool Hospital, NSW
Discover insights on what to discuss with patients with IBD in a pre-travel consultation.
Play Video

Smoking, Cannabis, Vaping/other Inhalations and their Impact on IBD

A/Prof Mayur Garg
Northern Health, VIC
Watch a topline, evidence-based review of the impact of smoking, vaping, and the use of cannabis in patients with IBD.
Play Video

Selling EEN to your Patient

A/Prof Daniel (Avi) Lemberg
Sydney Children’s Hospital, NSW
Get practical insights on the team approach to implementing exclusive enteral nutrition (EEN) in patients with Crohn’s disease.
Play Video

Should Shingrix Change your Practice?

A/Prof Graham Radford-Smith
Integrated Gut Health, QLD
Discover the factors influencing the risk of herpes zoster in patients with IBD and the strategies to implement the appropriate vaccination in your practice.
Play Video

Skin Cancer/BMD Screening

Dr Kate Lynch
Royal Adelaide Hospital, SA
Discover which IBD therapies are associated with an increased risk of skin cancer. The second part of this talk addresses the role of bone mineral density (BMD) screening in patients with IBD.
Play Video

Case study

Dr Michael De Gregorio
St Vincent’s Hospital, Melbourne
Watch two case study discussions in Crohn’s disease that weave in key points and extend the discussions from the previous presentations.

Panellists: Dr Astrid-Jane Williams, A/Prof Mayur Garg, A/Prof Daniel (Avi) Lemberg, Dr Kate Lynch, A/Prof Graham Radford-Smith
Play Video

Closing remarks

Prof Jane Andrews
Royal Adelaide Hospital
Watch Prof Andrews briefly wrap up the Dedicated to IBD meeting.

SPEAKER, CHAIR AND STEERING COMMITTEE BIOGRAPHIES

Steering Committee

Prof Jane Andrews
Royal Adelaide Hospital, SA

View full bio

Prof Ian Lawrance
St John of God Hospital, WA

View full bio

A/Prof Jakob Begun
Mater Hospital, QLD

View full bio

Prof Susan Connor
Liverpool Hospital, NSW

View full bio

A/Prof John Nik Ding
St Vincent's Hospital, VIC

View full bio

Speakers

Dr Alice Bennett
Crystal Brook, SA

View full bio

Dr Michael De Gregorio
St Vincent's Hospital, VIC

View full bio

A/Prof Mayur Garg
Northern Health, VIC

View full bio

Dr Simon Ghaly
St Vincent's Hospital, NSW

View full bio

Prof Peter Gibson
Monash University, VIC

View full bio

Dr Claire Gordon
Sir Charles Gairdner Hospital, WA

View full bio

Dr Yoon-Kyo An
Mater Hospital, QLD

View full bio

A/Prof Daniel (Avi) Lemberg
Sydney Children's Hospital, NSW

View full bio

Prof Rupert Leong
Concord Hospital, NSW

View full bio

Dr Kate Lynch
Royal Adelaide Hospital, SA

View full bio

A/Prof Graham Radford-smith
Integrated Gut Health, QLD

View full bio

Dr Gareth Walker
Royal Brisbane and Women's Hospital, QLD

View full bio

Dr Astrid-Jane Williams
Liverpool Hospital, NSW

View full bio

A/Prof Jonathan Segal
Royal Melbourne Hospital, VIC

View full bio

This content is intended for Healthcare Professionals only.
Copyright © 2023 Dr Falk Pharma Australia Pty Ltd. ABN 40 631 091 131. Level 10, 815 Pacific Highway, Chatswood NSW 2067.
Website: www.drfalkpharma.com.au Tel: 1800 DRFALK (1800 373 255). Email: admin@drfalkpharma.com.au
Date of preparation June 2023. IBD-2023-1209. DRFAL2312.